1. Grasemann H, Ratjen F. Cystic fibrosis. NEJM 2023; 398:1693-1707.
2. Farrel PM. The prevalance of cystic fibrosis mutations in European Union. J Cyst Fibros 2008; 7:179-196.
3. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938; 56: 344-399.
4. Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073.
5. ECFS Patient Registry 2022 Annual Report. https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports
6. Ulusal Kistik Fibrozis Hasta Kayıt Sistemi 2022 Yıllık Raporu. https://kistikfibrozisturkiye.org/hasta-kayıt-sistemi
7. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis tansmembrane conductance regulator gene. Nat Genet 2013; 45:1160-1167.
8. De Boeck K. Cystic fibrosis in year 2020: A disease with a new face. Acta Paediatr 2020 109:893-899.
9. Cutting GR. Modifier genes in mendelian disorders: the example of cystic fibrosis. Ann NY Acad Sci 2010; 1214:57-59.
10. Baucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007; 58:157-170.
11. Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax 2013; 68:1157-1162.
12. Wilschanski M, Novsk I. The cystic fibrosis of exocrine pancreas. Cold Spring Harbor Perspect Med 2013:1-17.
13. Chamnan P, Shine BS, Haworth CS, et al. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33:311-316.
14. Meyerholz DK, Stoltz D, Pezzulo AA, et al. Pathology of gastrointestinal organs in porcine model of cystic fibrosis. Am J Pathol 2010; 176:1377-1389
15. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23:545-549.
16. De Souza DAS, Faucz FR, Pereira-Ferraril, Santos Sotomaior V, Raskin S. Congenital bilateal absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and
genetic counseling. Andrology 2018; 6:127-135.
17. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care 2009; 54:618-625.
18. Cystic Fibrosis Trust. Laboratory Standards for Processing Microbiological Samples from People with Cystic Fibrosis. Second edition, December 2022.
19. Saiman L, Murray L, Brown AW. State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists. Clin Infect Dis.
2025 Jun 4;80(5): e65-e77.
20. Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024 Aug 8;10(1):53. UĞUR ESKİ 53. REF.
21. Thornton CS, Parkins MD. Microbial Epidemiology of the Cystic Fibrosis Airways: Past, Present, and Future. Semin Respir Crit Care Med. 2023; Apr;44(2):269-286.
22. Cystic Fibrosis Foundation Patient Registry 2023 Annual Data Report Bethesda, Maryland ©2024 Cystic Fibrosis Foundation.
23. ECFSPR Annual Report 2023, Zolin A, Adamoli A, Bakkeheim E; European Cystic Fibrosis Society 2025.
24. Ulusal Kistik Fibrozis Hasta Kayıt Sistemi 2023 Yılı Raporu. https://www.kistikfibrozisturkiye.org/hasta-kayit-sistemi/
25. Saiman L, Waters V, LiPuma JJ, et al. Practical guidance for clinical microbiology laboratories: updated guidance for processing respiratory tract samples from people with cystic fibrosis. Clin
Microbiol Rev 2024; 37: e0021521.
26. Ramond E, Lepissier A, Ding X, et al. Lung-Adapted Staphylococcus aureus isolates with dysfunctional agr system trigger a proinflammatory response. J Infect Dis 2022, 226:1276–1285.
27. Yagci S, Hascelik G, Dogru D, Ozcelik U, Sener B. Prevalence and genetic diversity of Staphylococcus aureus small-colony variants in cystic fibrosis patients. Clin Microbiol Infect. 2013
Jan;19(1):77-84.
28. Taccetti G, Terlizzi V, Campana S, et al. Antibiotic treatment of bacterial lung infections in cystic fibrosis. Eur J Pediatr. 2024 Dec 14;184(1):82.
29. Sunman B, Emiralioglu N, Hazirolan G, et al. Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pul-
monol. 2022 Jun;57(6):1456-1465.
30. Guliyeva A, Yilmaz Yegit C, Yanaz M, et al. Effective Pseudomonas aeruginosa Eradication in Cystic Fibrosis: Multicenter Study. Clin Pediatr (Phila). 2025 Nov; 64(11):1581-1588.
31. Parkins MD, Somayaji R, Waters VJ. Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis. Clin Microbiol Rev 2018; 31(04): e00019-18.
32. Green HD, Jones AM. Managing Pulmonary Infection in Adults With Cystic Fibrosis: Adult Cystic Fibrosis Series. Chest. 2022 Jul;162(1):66-75.
33. Blanchard AC, Waters VJ. Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection. J Pediatric Infect Dis Soc 2022; 11: Suppl 2: S3-S12.
34. Akışoğlu Ö, Engin D, Sarıçam S, Müştak HK, Şener B, Hasçelik G. Multilocus sequence analysis, biofilm production, antibiotic susceptibility and synergy tests of Burkholderia species in
patients with and without cystic fibrosis. Mikrobiyol Bul. 2019 Jan;53(1):22-36.
35. Sunman B, Emiralioglu N, Hazirolan G, et al. Impact of Achromobacter spp. isolation on clinical outcomes in children with cystic fibrosis. Pediatr Pulmonol. 2022 Mar; 57(3):658-666.
36. Prieto MD, Alam ME, Franciosi AN, Quon BS. Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis. ERJ Open Res. 2023
Jan 3;9(1):00336-2022.
37. Satana, D., Erkose-Genc, G., Tamay, Z. et al. Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients. Ann Clin Microbiol Antimicrob 13, 28 (2014).
38. Ademhan Tural, D., Emiralioglu, N., Ozsezen, B., et al. The frequency and related factors of non-tuberculosis mycobacteria infections among patients with cystic fibrosis. Pediatrics Interna-
tional, 2021; 63:1369-1375.
39. Saluzzo F, Riberi L, Messore B, et al. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells. 2022 Apr 6; 11(7):1243.
40. Harvey C, Weldon S, Elborn S, Downey DG, Taggart C. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis. Int J Mol Sci. 2022 Mar 23;23(7):3513.
41. Robertson JK, Goldberg JB. The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota. Microbiology (Reading). 2025
Apr;171(4):001553.
42. Mianowski L, Doléans-Jordheim A, Barraud L, et al. One year of ETI reduces lung bacterial colonisation in adults with cystic fibrosis. Sci Rep 2024; 14:29298.
43. Brody AS, Molina PL, Klein JS, et al. High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999; 29:731-
735.
44. Wielputz MO, Puderbach M, Kopp-Schneider A, et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.
Am J Respir Crit Care Med 2014; 189:956-965.
45. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cysic fibrosis. J Pediatr 1997; 131:809-814.
46. Aurora P, Bush A, Gustafsson P et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005; 171:249-256.
47. Kang SH, Dalcin Pde T, Piltaher OB, Migliavacca Rde O. Chronic rhinosinusitis and nasal polyposis in cystic fibrosis update on diagnosis and treatment. J Brasil Pnemol 2015;41:65-76.
48. Handelsman JA, Nasr SZ, Pitts C, et al. Prevalance of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides. Ped Pulmonol 2017; 52:1157-1162.
49. Ooi CY, Durie PR. Cystic fibrosis from gastroenterologist perspective. Nature Rev 2016; 13:175-185.
50. Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 2013; 12:116-124.
51. Dupuis A, Keenan K, Ooi CY, et al. Prevalance of mecoium ileus marks the severity of mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genet Med 2016;
18:333-340.
52. Colombo C, Ellemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal instestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011: 10: S24-28.
53. Demeyer S, De Boeck K, Witters P, et al. Beyond pancreatic insufficiency and liver disease in cystic fibrosis. Eur J Pediatr 2016; 175:881-894.
54. Maisonneuve P, Fitz Simmons SC, Neglia JP, et al. Cancer risk in non-transplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003; 95:381-387.
55. O’Riordan SM, Robinson PD, Donagdue KC, Moran AM. Management of cystic-fibrosis related diabetes. Pediatric Diabetes 2008; 9:338-344.
56. Aswani N, Taylor CJ, McGaw J et al. Pubertal growth and development in cystic fibrosis: a retrospective review. Acta Paediatr 2003; 92:1029-1032.
57. Marquette M, Hawort CS. Bone health and disease in cystic fibrosis. Padiatr Respir Rev 2016;20: S2-5.
58. McCallum TJ, Milunsky JM, Cunningham DL et al. Fertility in men with cystic fibrosis: an update on current surgical practices and outcomes. Chest 2000, 118:1059-1062.
59. Sismanlar Eyuboglu T, Dogru D, Cakir E, et al. Clinical features and accompanying findings of Pseudo Bartter Syndrome in cystic fibrosis. Ped Pulmonol 2020; 55:2011-2016.
60. Quittner AL Abbott J, Georgiopoulos AM, et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus
statements for screening. Thorax 2016; 71:26-34.
61. Cohen-Cymberknoh M, Tanny T, Breuer O, et al. Attention deficit hyperreactivity disorder symptoms in patients with cystic fibrosis. J Cyst Fibros 2018; 17:281-228.
62. Farrell PM, White TB, Howenstine MS, et al. Diagnosis of cystic fibrosis in screened populations. J Pediatrics 2016; 181S: S33-44.
63. De Boeck K, Vermeulen F, Deupont L. The diagnosis of cystic fibrosis. Presse Med 2017; 46: e97-e108.
64. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential difference: an out-come measure in multicenter cystic fibrosis clinical trials. Pediatr
Pulmonol 2004; 37:385-392.
65. De Boeck K, Derichs N, Fajac I, et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fib 2011; suppl 2: S53-66.
66. CFTR1 database (http:///www.genet.sickkids.on.ca/app)
67. CFTR2 database (http://www.cftr2.org),
68. CF-France(http://cftr.iurc.montp.inserm.fr)
69. Brewington J, Clancy JP. Diagnostic testing in cystic fibrosis. Clin Chest Med 2016; 37:31-46.
70. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 2001; 107:1-13.
71. Sontag MK, Lee R, Wright D, et al. Improving the sensitivity and positive predictive value in a cystic fibrosis newborn screening program using a repeat immune-reactive trypsinogen and
genetic analysis. J Pediatr 2016; 175:150-158.
72. T.C Sağlık Bakanlığı, Halk Sağlığı Genel müdürlüğü Çocuk ve Ergen Sağlığı Daire Başkanlığı Yenidoğan Metabolik ve Endokrin Hastalık Tarama Programı (NPT). https://hsgm.saglik.gov.tr/
tr/tarama-programlari/ntp.html
73. Pagin A, Sermet-Gaudelus I, Burgel PR. Genetic diagnosis in practice: From cystic fibrosis. Arch Pediatrie 2020;27:eS25-29.
74. Gavillet H, Hatfield L, Rivett D, et al. Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis. Microbiol Spectr. 2022 Oct 26;10(5): e0041922.
75. Schoonbroodt S, Ichanté JL, Boffé S, et al. Real-time PCR has advantages over culture-based methods in identifying major airway bacterial pathogens in chronic obstructive pulmonary dise-
ase: Results from three clinical studies in Europe and North America. Front Microbiol. 2023 Feb 24; 13:1098133.
76. Kotnik Pirš, A., Krivec, U., Simčič, S. et al. Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas
aeruginosa infection in children with cystic fibrosis. BMC Pulm Med, 2016; 16, 161.
77. Doğru D, Pekcan S, Yalçın E, et al. The role of serum Pseudomonas aeruginosa antibodies in the diagnosis and follow-up of cystic fibrosis. Turk J Pediatr. 2013 Jan-Feb; 55(1):50-7.
78. Drevinek, P., Canton, R., Johansen, H. K., et al. New concepts in antimicrobial resistance in cystic fibrosis respiratory infections. Journal of Cystic Fibrosis, 2022; 21: 937-945.
79. Lloyd EC, Cogen JD, Maples H, Bell SC, Saiman L. Antimicrobial Stewardship in Cystic Fibrosis. J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement 2): S53-S61.
80. Edmondson C, Davies JC. Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. Ther Adv Chronic Dis 2016; 170-183.
81. Royal Bromphton Hospital. Clinical Guidelines Care of Children with Cystic Fibrosis 2023 (www.rbht.nhs.uk/childrencf)
82. Michelson P, Faro A, Ferkol T. Kendig’s disorders of the respiratory tracts in children. In Wilmott RW, Detering R, Li A, Ratjen F, Sly P, Zar HJ, Bush A (eds). Pulmonary Disease in Cystic
Fibrosis, 9th eds. Elsevier Philladephia, 2019; pp:777-787.
83. Castellani C, Duff A, Bell SC, et al. ECFS Best Practice Guidelines: the 2018 revision. J Cystic fibrosis 2018: 17:153-178.
84. Rosenfeld M, EmersonJ, Williams-Warren J et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
85. Snell G, Reed A, Stern M, et al. The evoluation of lung transplantation for cystic fibrosis: a 2017 update. J Cyst Fibr 2017; 16:553-564.
86. Southern KW, Castellani C, Lammertyn E, et al. Standarts of care for CFTR-variant spesific therapy (including modulators) for people with cystic fibrosis. J Cyst Fibros 2023; 22:17-30.
87. Hoppe JE, Kasi SA, Pittman JE. Vanzacaftor- tezacaftor- deutivacaftor for children 6-11 years with cystic fibrosis (RIPGELINE Trial (Vx21-121-105): an analysis from a single arm, phase 3
trial. Lancet Respir Med 2025;13:244-55.
88. Wilschanski M, Munch A, Carrien E, et al. ESPEN- ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr 2024; 43:413-445